AGN:CSE; AGNPF:OTCQB; AGW:FSE

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.

AGN:CSE AGNPF:OTCQB AGW:FSE

View Company News

Visit Company Website

Expert Comments:

This Pharmaceutical Company Has a Brilliant Concept
(1/17/22)

Clive Maund, CliveMaund.com

(1/12/22)

"Long-term charts show Algernon Pharmaceuticals Inc. stock to be very cheap. As it now has only 1.6M shares in issue after a 1 for 100 rollback, it has big upside potential. . .the company remains a Buy here and especially on any minor dips, if any."

Co. Looks To US For Help Fighting Strokes
(12/29/21)

Clive Maund, CliveMaund.com

(12/22/21)

"Algernon Pharmaceuticals Inc. stock has now arrived at what looks like a long-term cyclical low at the support at its late 2019 lows, which is a good point for it to turn, and that's what it looks like it is in the process of doing. . .the fundamentals of the company are believed to be positive. The conclusion is that Algernon is rated an attractive Speculative Buy here."

Clive Maund, CliveMaund.com

(12/12/21)

"Algernon Pharmaceuticals Inc. has some good things going on. The stock looks like it is at or close to a cyclical low, especially as volume has built up dramatically over the past month in a manner that is characteristic of a bottom, with upside volume kicking in in recent days. . .we could soon see some good gains in this stock."

André Uddin, Research Capital Corporation

(12/6/21)

"Algernon Pharmaceuticals Inc.'s Ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough. . .the company expects to complete patient enrollment of the study by 2021E, with results anticipated in Q2/22. . .Algernon is a Phase 2-stage drug development company, yet it has a market cap of CA$7M. We believe its risk/reward profile is attractive."

Biopharma Expands Clinical Program of Lead Drug Candidate to Treat Chronic Cough
(9/29/21)

Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial.

Pharma Developer Licenses Patent for Treating Neuroendocrine Cancers from US Ivy League College
(8/10/21)

Algernon Pharmaceuticals reported its acquisition of the exclusive rights from Dartmouth College for a method of use patent for use in treatment of neuroendocrine cancers expressing functional NMDA receptors.

André Uddin, Research Capital Corporation

(8/4/21)

Algernon Pharmaceuticals Inc. has decided to terminate the development of Ifenprodil for COVID-19. . .we agree with management that the risk-benefit profile of the COVID-19 program does not justify its continuation; we view the company's move as wise. . .Algernon is switching focus to the idiopathic pulmonary fibrosis/chronic cough indication."

Sam Riches, Weekend Dispensary

(5/22/21)

"Algernon Pharmaceuticals Inc. says it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its planned Phase 1 clinical trial, which is set to begin later this year with the U.K.-based Hammersmith Medicines Research. . .Algernon believes its approach could potentially lead to a breakthrough therapy designation from the FDA, which enables priority review and can fast track the clinical trial process."

More Expert Comments

	André Uddin, Research Capital Corporation (5/10/21) "Algernon Pharmaceuticals Inc. has recently filed an end-of-Phase 2 meeting request with the U.S. Food and Drug Administration to discuss advancing ifenprodil to the Phase 3 part of the Phase 2b/3 trial in COVID-19. . .ifenprodil is in a Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough, for which results are expected in H2/21. DMT, a repurposed psychedelic compound, is expected to enter into a Phase 1 trial in stroke in H2/21."

André Uddin, Research Capital Corporation (3/1/21) "The database of the Phase 2b part of Algernon Pharmaceuticals Inc.'s Phase 2b/3 trial with ifenprodil in COVID-19 is to be locked for analysis on March 5, 2021; final results are expected to be disclosed shortly thereafter. Results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis/chronic cough are expected in Q2/21 or Q3/21 for early chronic cough data and Q4/21 for full study data."

André Uddin, Research Capital Corporation (2/2/21) "Algernon Pharmaceuticals Inc. has established a program to repurpose a psychedelic compound, DMT, for stroke. . .the company is to continue a number of preclinical studies with DMT for stroke and is looking to file an investigational new drug application with the U.S. Food and Drug Administration based on DMT's historical data of Phase 1 clinical trials and new preclinical data generated by Algernon."

Clive Maund, CliveMaund.com (2/1/21) "Algernon Pharmaceuticals Inc. is looking like a Buy again here as it is at the bottom of the shallow uptrend that has developed from the December low, and a stop may be placed beneath the lower rail of the channel. An additional reason for buying the company here that may lead to a bigger move is the good news out of it this morning that it is commencing clinical research with a psychedelic drug for stroke treatment."

Clive Maund, CliveMaund.com (12/28/20) "The good news with Algernon Pharmaceuticals Inc. is that the stock has now arrived at a much stronger long-term support level in a deeply oversold state, so the least we can expect is a significant bounce from here. On Thursday there was a moderately bullish candle on strong volume with it closing well off the lows, which suggests that it may be reversing here or at least have hit bottom."

	André Uddin, Research Capital Corporation (12/15/20) "Algernon Pharmaceuticals Inc. reports interim results of a COVID-19 Phase 2b/3 trial with Ifenprodil. . .The results showed two positive early trends in high-dose ifenprodil at Day 15: (i) fewer patients required mechanical ventilation and (ii) the reduction of the NEWS score (used to monitor patient status) was quicker, which could potentially translate to a faster recovery down the road. . .We are maintaining our SPECULATIVE BUY rating and TP of $0.80/share. AGN remains a high risk high reward investment opportunity."

Clive Maund, CliveMaund.com (12/8/20) "Algernon Pharmaceuticals Inc. is now in a vigorous uptrend. It has paused for a rest in recent days with a small bull Pennant believed to be forming. Current light volume and strong Accumulation line suggest that another upleg is imminent."

All Penny Stocks (8/24/20) "What a spectacular run junior biotech Algernon Pharmaceuticals Inc. has made since late-November. The stock run-up is largely predicated on one virus, COVID-19. With a brief pullback over the last few months, we think it is time to revisit this stock as the technical stars may be aligning for one more major push higher."

	André Uddin, Research Capital Corporation (8/19/20) "We are initiating coverage of Algernon Pharmaceuticals Inc. with a Speculative Buy recommendation and a target price of $0.80/share. . .Algernon is focused on developing repurposed small molecules for new disease indications – these drug candidates have been already approved in ROW markets (but not approved in the U.S. or Europe). . .Algernon's lead product, ifenprodil (a marketed drug in Japan for circulatory disorders) is being repurposed for COVID-19, idiopathic pulmonary fibrosis (IPF) and chronic cough."

Baystreet (8/12/20) "Algernon Pharmaceuticals Inc. is betting that this quiet and unassuming safe generic drug, Ifenprodil, may soon become a global blockbuster. . .the company recently announced the first patient has been enrolled in its multinational human Phase 2b/3 COVID trial of Ifenprodil. . .Phase 2b data are expected before 2020E."

Experts Following This Company

Dr. KSS, Founder and Editor-in-Chief – BioPub.co
Clive Maund – CliveMaund.com
	Penny Queen, Mother, Investor and Social Media Leader
	André Uddin – Research Capital Corporation

Company News

1/19/2022 – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

1/14/2022 – Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

12/8/2021 – Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

12/2/2021 – Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

11/30/2021 – Algernon Pharmaceuticals Announces New Chief Financial Officer

11/24/2021 – Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

11/23/2021 – Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

11/19/2021 – Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

11/1/2021 – Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

10/21/2021 – Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights

	Advancing new drug treatments for billion dollar global disease markets.
	Conducting multiple phase II clinical trials
	Experienced management team & globally recognized medical advisory board

catalyst Calendar

Q2 2021	U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4 2021	Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4 2021	Phase 1 Study planned for DMT, Q4 2021